REQUEST A DEMO
Total
USD $0.00
Search more companies

Cureworth Drugs & Intermediates Private Limited (India)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Cureworth Drugs & Intermediates Private Limited Profile Updated: November 22, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Cureworth Drugs & Intermediates Private Limited is an unlisted company, incorporated on 14/06/2010. It has its registered office in the State of Maharashtra, India. Company's corporate identification number (CIN) is U24232MH2010PTC204157 and registration number is 204157.

Headquarters
Plot No. G-48 2Nd Floor Anjani Niwas Sector No. 12 Kharghar Raigarh (Mh) Panvel In-Mh In 410210
Raigad; Maharashtra; Postal Code: 410210

Contact Details: Purchase the Cureworth Drugs & Intermediates Private Limited report to view the information.

Basic Information
Total Employees:
Purchase the Cureworth Drugs & Intermediates Private Limited report to view the information.
Outstanding Shares:
Purchase the Cureworth Drugs & Intermediates Private Limited report to view the information.
Registered Capital:
Purchase the Cureworth Drugs & Intermediates Private Limited report to view the information.
Incorporation Date:
June 14, 2010
Key Executives
Purchase this report to view the information.
Promoter Director
Purchase this report to view the information.
Promoter Director
Company Performance
Financial values in the chart are available after Cureworth Drugs & Intermediates Private Limited report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency INR. Absolute financial data is included in the purchased report.
Net sales revenue
3.02%
Total operating revenue
3.07%
Operating profit (EBIT)
45.07%
EBITDA
15.36%
Net Profit (Loss) for the Period
11.13%
Total assets
-1.84%
Total equity
3.2%
Operating Profit Margin (ROS)
0.34%
Net Profit Margin
0.05%
Return on Equity (ROE)
0.22%
Debt to Equity Ratio
-31.5%
Quick Ratio
0.05%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?